The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 307.00
Ask: 312.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.629%)
Open: 311.00
High: 314.00
Low: 303.00
Prev. Close: 310.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Cordiant deploys IPO funds; Scotgold gets loan

Tue, 04th May 2021 20:25

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Cordiant Digital Infrastructure Ltd - investment firm focused on digital infrastructure assets - Announces deployment or commitment of substantially all of the net proceeds from its IPO into digital infrastructure platforms in the Czech Republic and Norway. Company has completed the acquisition of Ceske Radiokomunikace and entered into a legally binding letter of intent to acquire a Norwegian fibre network and certain land for data centre development for a combined total consideration of GBP451 million, comprising GBP318 million of equity and the assumption of an amount equal to GBP133 million of debt. Adds it has raised its dividend guidance, now targeting "no less than 3 pence per share" for the current financial year, up from 1p. Firm floated in London in February.

----------

Hutchmed (China) Ltd - Hong-Kong-based pharmaceutical company - Completes rolling submission of a new drug application to the US FDA for surufatinib for the treatment of pancreatic and extra-pancreatic neuroendocrine tumors. "Having successfully launched surufatinib in China early this year, we are now looking forward, subject to its approval, to being able to provide access to this important new therapeutic option for NETs patients in the US and beyond," says Marek Kania, managing director & chief medical officer of Hutchmed International Corp.

----------

AfriTin Mining Ltd - tin miner with asset in Namibia - Says definitive feasibility study confirms the feasibility of expanding the current phase 1 processing plant, resulting in a 67% increase in tin concentrate production to 1,200 tonnes per year from 720 tonnes. "The DFS confirms the highly attractive economics from a low-cost modular expansion of the current phase 1 at Uis which can be implemented in eight months. The DFS also coincides with the company achieving its first full quarter of steady state production at the phase 1 plant as a global tin prices reach a 10-year high," says Chief Executive Anthony Viljoen.

----------

SDX Energy PLC - London-headquartered oil and gas exploration, production, and development company - Starts the first phase of its 2021 drilling campaign in Morocco, which will comprise up to five wells over the year. The first phase will consist of three appraisal/development wells. The second phase of the Moroccan drilling campaign will commence in the autumn.

----------

Intelligent Ultrasound Group PLC - Cardiff, Wales-based artificial intelligence ultrasound software firm - Successfully registers with the MHRA to market ScanNav Anatomy: Peripheral Nerve Block in the UK and will be launching the product into the UK market at the forthcoming RA-UK annual scientific meeting. Continues to progress regulatory filing with US Food & Drug Administration, as well as seeking to licence an integrated version of the product to major ultrasound manufacturers. "ScanNav PNB uses the latest AI technology to automatically highlight the live ultrasound image to enhance the accuracy and standardisation of ultrasound image interpretation, by making it easier to identify key anatomical structures," company explains.

----------

CAP-XX Ltd - Australia-based supercapacitors and energy management systems manufacturer - Says Jack, developer of the first windshield breakage detection solution, has selected the CAP-XX HS208F supercap for its solar-powered Internet-of-Things device. "We are proud to provide the high energy and power density Jack needs to power its advanced communication system," said Anthony Kongats, chief executive at CAP-XX. "This is just one of the many possible applications for thin CAP-XX supercapacitors in IoT devices."

----------

Panther Metals PLC - company focused on mineral exploration in Canada and Australia - Receives new exploration permit to proceed with the revised plans for reconnaissance diamond drilling, ground induced polarisation geophysics and trenching focussed on testing intrusive contact shear-zone hosted gold mineralisation in the vicinity of the north shore of Dotted Lake. The new permit will allow Panther to drill up to 8 diamond drill holes this season where initial results warrant. The new permit extends these exploration permissions for three years to April 26, 2024. "This receipt now facilitates us to move our revised plans forward and we are currently engaging with potential contractors with a view to drill at the earliest opportunity," says Chief Executive Darren Hazelwood.

----------

Tribal Group PLC - provider of education software and services - Has acquired and paid for the remaining issued share capital of Semestry Limited, a supplier of cloud based scheduling and timetabling software to the higher education market. "Semestry has traded in line with expectations since the acquisition and the integration is progressing to plan," says Tribal.

----------

Secured Income Fund PLC - investor focused on SME loan assets and secured lending opportunities - Will return GBP3.7 million to shareholders via a second return of capital by the issue of B shares. Proceeds from the redemption of the B shares is equivalent to 7.0p per ordinary share, firm says. Capital being returned represents around 11% of company's net asset value as at end of March.

----------

Power Metal Resources PLC - metal exploration and development company - Establishes new 100%-owned and subsidiary 'incubator' business, Power Capital Investments Ltd, which will be initially be fully funded by the company. "Power Capital will actively identify small, entrepreneurial business ventures with significant growth potential in the junior resource space and provide support with regard to business management, project development and corporate development to enable them to scale rapidly and realise their potential. Power Capital may also provide financial support," Power Metal Resources explains.

----------

Scotgold Resources Ltd - gold exploration and production company focused on Scotland - Gets short-term loan of GBP2 million from group comprising Non-Executive Chair Nathaniel le Roux; non-executive directors Bill Styslinger, Peter Hetherington and Ian Proctor; and an unrelated third party. Loan provided to SGZ Cononish Ltd, a wholly-owned subsidiary of Scotgold.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
29 Aug 2023 09:30

IN BRIEF: China grants Hutchmed's savolitinib breakthrough therapy tag

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Wins 'breakthrough therapy designation' in China for its gastric cancer treatment, savolitinib. The BTD is granted by the National Medical Products Administration. It is for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with mesenchymal epithelial transition factor amplification who have failed at least two lines of standard therapies. Hutchmed notes that MET-driven gastric cancer has a poor prognosis, and China grants a BTD to new drugs that treat life-threatening diseases for which there are no effective treatment options.

Read more
21 Aug 2023 08:46

Hutchmed China hails trial on sovleplenib meeting primary endpoint

(Alliance News) - Hutchmed (China) Ltd on Monday said a phase 3 trial evaluating the investigational use of sovleplenib met its primary endpoint.

Read more
21 Aug 2023 08:24

Hutchmed meets all endpoints in platelet disorder treatment trial

(Sharecast News) - Hutchmed China reported a breakthrough from its recent phase three trial in sovleplenib on Monday, reporting that it met its primary endpoint and all secondary endpoints for treating adult patients with primary immune thrombocytopenia - a platelet disorder - (ITP) in China.

Read more
31 Jul 2023 12:47

Hutchmed swings to profit after "sharpening goals and priorities"

(Alliance News) - Hutchmed (China) Ltd on Monday reported sharp first-half revenue growth, as a strategy change to boost its fortunes outside of China saw early fruit.

Read more
24 Jul 2023 15:46

UK earnings, trading statements calendar - next 7 days

Tuesday 25 July 
City of London Investment Group PLCTrading Statement
Compass Group PLCTrading Statement
Croda International PLCHalf Year Results
Games Workshop Group PLCFull Year Results
Greencore Group PLCTrading Statement
Hummingbird Resources PLCTrading Statement
MITIE Group PLCTrading Statement
Paragon Banking Group PLCTrading Statement
Reach PLCHalf Year Results
Smart Metering Systems PLCTrading Statement
Tristel PLCTrading Statement
Tyman PLCHalf Year Results
Unilever PLCHalf Year Results
Unite Group PLCHalf Year Results
Wednesday 26 July 
Aptitude Software Group PLCHalf Year Results
Breedon Group PLCHalf Year Results
Conduit Holdings LtdHalf Year Results
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
FRP Advisory Group PLCFull Year Results
Gresham Technologies PLCHalf Year Results
Lloyds Banking Group PLCHalf Year Results
Marston's PLCTrading Statement
Nichols PLCHalf Year Results
Primary Health Properties PLCHalf Year Results
Rathbones Group PLCHalf Year Results
Revolution Bars Group PLCTrading Statement
Rio Tinto PLCHalf Year Results
Science Group PLCHalf Year Results
Van Elle Holdings PLCFull Year Results
Thursday 27 July 
Allianz Technology Trust PLCHalf Year Results
Antofagasta PLCHalf Year Results
Capital & Regional PLCHalf Year Results
Card Factory PLCTrading Statement
Checkit PLCTrading Statement
Drax Group PLCHalf Year Results
Deliveroo PLCHalf Year Results
Derwent London PLCHalf Year Results
Entain PLCHalf Year Results
Greencoat UK Wind PLCHalf Year Results
Global Connectivity PLCHalf Year Results
Hostelworld Group PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Lancashire Holdings LtdHalf Year Results
Mitchells & Butlers PLCTrading Statement
OSB Group PLCHalf Year Results
Persimmon PLCHalf Year Results
Petrofac LtdHalf Year Results
Redcentric PLCFull Year Results
S&U PLCTrading Statement
Savills PLCHalf Year Results
Secure Trust Bank PLCHalf Year Results
Spirax-Sarco Engineering PLCHalf Year Results
Videndum PLCHalf Year Results
Wheaton Precious Metals CorpHalf Year Results
Friday 28 July 
AIB Group PLCHalf Year Results
GCP Infrastructure Investments LtdTrading Statement
International Consolidated Airlines Group SAHalf Year Results
Intertek Group PLCHalf Year Results
Jardine Matheson Holdings LtdHalf Year Results
NatWest Group PLCHalf Year Results
PayPoint PLCFull Year Results
PayPoint PLCTrading Statement
Standard Chartered PLCHalf Year Results
YouGov PLCTrading Statement
Monday 31 July 
Hutchmed (China) LtdHalf Year Results
Pearson PLCHalf Year Results
Pod Point Group Holdings PLCHalf Year Results
Quartix Technologies PLCHalf Year Results
Spectris PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
20 Jul 2023 14:14

IN BRIEF: Hutchmed progresses fruquintinib designation and testing

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Granted breakthrough therapy designation, by the Center for Drug Evaluation of China's National Medical Products Administration, for oral inhibitor fruquintinib combined with PD-1 antibody sintilimab. BTD is for treatment of patients with previously treated advanced endometrial cancer.

Read more
10 Jul 2023 12:58

Hutchmed launches new phase one study in China

(Sharecast News) - Biopharmaceutical company Hutchmed China announced the launch of a phase one study in China for HMPL-415 on Monday - an investigational selective allosteric inhibitor that targeted Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2).

Read more
10 Jul 2023 08:53

IN BRIEF: Hutchmed starts study for tumour treatment in China

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases' treatment developer - Starts phase one study in China of its SHP2 inhibitor HMPL-415 for the treatment of advanced malignant solid tumours. First patient received their first dose on Thursday last week. Hutchmed expects up to 80 patients to take part in the study. SHP2 is a non-receptor protein tyrosine phosphatase which controls cell growth and cell migration.

Read more
16 Jun 2023 08:51

Hutchmed, Takeda Fresco-2 study published in The Lancet

(Alliance News) - Hutchmed (China) Ltd on Friday said phase three results for its Fresco-2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer, conducted alongside Takeda Pharmaceutical Co Ltd, were published in peer-reviewed journal, The Lancet.

Read more
16 Jun 2023 08:44

Hutchmed China's colorectal cancer study to be published

(Sharecast News) - Hutchmed China, alongside its partner Takeda, announced the publication of the phase three 'FRESCO-2' study results evaluating the use of fruquintinib in patients with previously-treated metastatic colorectal cancer (CRC) on Friday, in the Lancet medical journal.

Read more
15 Jun 2023 16:51

IN BRIEF: Hutchmed and Takeda get Europe marketing backing for drug

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases treatment developer - Says marketing authorisation application for fruquintinib, made alongside Tokyo-based Takeda Pharmaceutical Co Ltd, has been validated and caccepted by the European Medicines Agency. Fruquintinib is an inhibitor of vascular endothelial growth factor receptors used to treat cancers.

Read more
26 May 2023 13:13

US FDA gives priority to Hutchmed's colorectal cancer treatment

(Sharecast News) - Hutchmed China, in collaboration with Takeda, announced on Friday that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of fruquintinib.

Read more
26 May 2023 08:56

Hutchmed China celebrates FDA review, teases new data at ASCO meeting

(Alliance News) - Hutchmed China Ltd on Friday celebrated a priority review granted by the US FDA for its cancer drug fruquintinib, and promised to present new data for this and two other therapies at the American Society of Clinical Oncology next month.

Read more
5 May 2023 15:57

UK shareholder meetings calendar - next 7 days

Monday 8 May 
no events scheduled 
Tuesday 9 May 
Caledonia Mining Corp PLCAGM
Direct Line Insurance Group PLCAGM
Foxtons Group PLCAGM
Hostelworld Group PLCAGM
IWG PLCAGM
Just Group PLCAGM
Midwich Group PLCAGM
Osirium Technologies PLCAGM
Windward LtdAGM
Wednesday 10 May 
abrdn PLCAGM
Antofagasta PLCAGM
Cenkos Securities PLCAGM
Ecora Resources PLCAGM
H&T Group PLCAGM
Harbour Energy PLCAGM
Jupiter Fund Management PLCAGM
Literacy Capital PLCAGM
Luceco PLCAGM
Marshalls PLCAGM
National Express Group PLCAGM
Renewables Infrastructure Group LtdAGM
Rentokil Initial PLCAGM
Seplat Energy PLCAGM
Spirax-Sarco Engineering PLCAGM
TClarke PLCAGM
Thursday 11 May 
88 Energy LtdAGM
Cairn Homes PLCAGM
Capita PLCAGM
Clarkson PLCAGM
Costain Group PLCAGM
Eleco PLCAGM
Eurocell PLCAGM
FBD Holdings PLCAGM
Genedrive PLCGM re Equity Prepayment Facility
Genel Energy PLCAGM
Gresham House PLCAGM
Gym Group PLCAGM
Hiscox LtdAGM
Irish Continental Group PLCAGM
John Wood Group PLCAGM
MyHealthChecked PLCAGM
OSB Group PLCAGM
Poolbeg Pharma PLCAGM
Rolls-Royce Holdings PLCAGM
Serinus Energy PLCAGM
Uniphar PLCAGM
Videndum PLCAGM
WAG Payment Solutions PLCAGM
Friday 12 May 
Balfour Beatty PLCAGM
Derwent London PLCAGM
Goodbody Health LtdAGM
GreenRoc Mining PLCAGM
Hutchmed (China) LtdAGM
Itim Group PLCAGM
Itsarm PLCGM re delisting from AIM
Wheaton Precious Metals CorpAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
18 Apr 2023 12:30

Hutchmed's gastric cancer treatment accepted for review in China

(Sharecast News) - Hutchmed China announced on Tuesday that its new drug application (NDA) for fruquintinib, in combination with paclitaxel has been accepted for review by the National Medical Products Administration (NMPA) in China.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.